A Phase 2 Interventional Study of Mesalamine in Preventing Colitis
Recruiting Phase 2 NCT05663775
Study Description
Evaluating the Effectiveness of Mesalamine in Preventing Bowel Inflammation in Patients Receiving Immunotherapy Treatment
Study Details
- Registry ID:
- NCT05663775
- Conditions:
- Immune-related Adverse Event, Diarrhea, Advanced Melanoma, Advanced Rectal Carcinoma
- Phase:
- Phase 2
- Target Enrollment:
- 20 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Cross Cancer Institute
Edmonton, Alberta, Canada
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.